{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"AMIGO-1","nct_id":"NCT05299125","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=amigo-1-nct05299125. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AMIGO-1","arms":[{"description":"CYCLE 1 (21-day cycle) Amivantamab 1400 mg (1750 mg if body weight is \\>80 kg) IV once weekly + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1\n\nCYCLE 2 (21-day cycle) Amivantamab 1400 mg (1750 mg if body weight is \\>80 kg) IV on day 1 + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1\n\nMAINTENANCE CYCLES 3 - 8 (21-day cycle) Amivantamab 1750 mg (2100 mg if body weight is \\>80 kg) IV on day 1 + Lazertinib 240 mg po daily + Pemetrexed 500 mg/m² IV on day 1\n\nMAINTENANCE CYCLES 9 + (21-day cycle) Amivantamab 1750 mg (2100 mg if body weight is \\>80 kg) IV on day 1 + Lazertinib 240 mg po daily","label":"Single Arm: Therapy consisting of lazertinib plus amivantamab plus chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Janssen, LP"],"completion_date":{"date":"2025-11-21","type":"ACTUAL"},"conditions":["Metastatic Non-small Cell Lung Cancers"],"enrollment":{"count":54,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Amivantamab","otherNames":[],"type":"DRUG"},{"name":"Lazertinib","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed 500 mg","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"Latin American Cooperative Oncology Group","official_title":"A Single Arm, Phase 2 Study of Amivantamab, Lazertinib and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers (NSCLCs) With EGFR Mutations","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-08-19","type":"ACTUAL"},"primary_outcomes":[{"measure":"To evaluate the 18-month progression-free survival (PFS) rate","timeFrame":"18 months"}],"references":[],"start_date":{"date":"2023-05-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations","url":"https://clinicaltrials.gov/study/NCT05299125"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/amigo-1-nct05299125"}